Biohaven Pharmaceutical Holding Co Ltd (BHVN) - Total Liabilities

Latest as of December 2025: $399.38 Million USD

Based on the latest financial reports, Biohaven Pharmaceutical Holding Co Ltd (BHVN) has total liabilities worth $399.38 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BHVN operating cash flow to assess how effectively this company generates cash.

Biohaven Pharmaceutical Holding Co Ltd - Total Liabilities Trend (2017–2025)

This chart illustrates how Biohaven Pharmaceutical Holding Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Biohaven Pharmaceutical Holding Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Biohaven Pharmaceutical Holding Co Ltd Competitors by Total Liabilities

The table below lists competitors of Biohaven Pharmaceutical Holding Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
NGL Energy Partners LP NYSE:NGL	USA	$3.79 Billion
Guangdong Marubi Biotechnology Co SHG:603983	China	CN¥1.46 Billion
Guangzhou Sanfu New Materials Technology Co. Ltd. A SHG:688359	China	CN¥602.52 Million
Mullen Group Ltd. TO:MTL	Canada	CA$1.43 Billion
Fila Holdings Corp KO:081660	Korea	₩2.75 Trillion
Resilient Property Income Fund Ltd JSE:RES	South Africa	ZAC14.54 Billion
Faraday Technology Corp TW:3035	Taiwan	NT$5.40 Billion
Henan Thinker Automation SHG:603508	China	CN¥309.15 Million

Liability Composition Analysis (2017–2025)

This chart breaks down Biohaven Pharmaceutical Holding Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Biohaven Pharmaceutical Holding Co Ltd stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.18	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	7.67	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.88	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Biohaven Pharmaceutical Holding Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Biohaven Pharmaceutical Holding Co Ltd (2017–2025)

The table below shows the annual total liabilities of Biohaven Pharmaceutical Holding Co Ltd from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	$399.38 Million	+108.36%
2024-12-31	$191.67 Million	+124.87%
2023-12-31	$85.24 Million	-30.71%
2022-12-31	$123.01 Million	+159.68%
2021-12-31	$47.37 Million	+36.44%
2020-12-31	$34.72 Million	-90.13%
2019-12-31	$351.69 Million	+152.85%
2018-12-31	$139.09 Million	+832.44%
2017-12-31	$14.92 Million	--

About Biohaven Pharmaceutical Holding Co Ltd

NYSE:BHVN USA Biotechnology

Market Cap

$1.51 Billion

Market Cap Rank

#7456 Global

#2119 in USA

Share Price

$10.04

Change (1 day)

+3.40%

52-Week Range

$7.79 - $20.56

All Time High

$59.75